BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

Immix Biopharma (IMMX)Immix Biopharma2026-06-25 13:46 ESTCompany update

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:

10 years of market exclusivity once authorized in the EU

Access to the EU centralized authorization procedure

Reduced fees for EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing...

Open original release

Related news

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Proposed Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma 12 Month Review Progress Update

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative

IMMXImmix Biopharma2026-06-25 13:46 EST

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

View all latest news

Immix Biopharma

Immix Biopharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

IMMXImmix Biopharma2026-06-26 10:00 EST

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-26 10:00 EST

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-06-26 10:00 EST

Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2

IMMXImmix Biopharma2026-06-26 10:00 EST

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

IMMXImmix Biopharma2026-06-26 10:00 EST

Immix Biopharma Announces Proposed Public Offering of Common Stock

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States